^
Association details:
| Biomarker: | KRAS mutation |
|---|---|
| Cancer: | Colorectal Cancer |
| Drug: | felezonexor (CBS9106) (XPO1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
564P - Updated results of a phase I study of Felezonexor (SL-801), a novel XPO-1 reversible inhibitor, in patients with relapsed/refractory solid tumours
Published date:
09/14/2020
Excerpt:
...57 patients (53% female), with a median age of 62 years (range: 39-85 years), received felezonexor monotherapy...A partial response lasting 7 months was achieved in a patient with heavily-retreated, K-RAS+ colorectal cancer...demonstrated safety and activity of felezonexor in a heavily pre-treated cohort of patients with advanced, poor prognosis tumours.
Trial ID:
